Alle Studien
RekrutierungPHASE2, PHASE3INTERVENTIONELL

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

This research is looking into a new gene therapy, RGX-202, for Duchenne muscular dystrophy (DMD). DMD is a condition where muscles weaken over time because a vital protein called dystrophin is missing. RGX-202 is designed to help muscle cells make a working version of this protein. The study will test how safe the treatment is, how well people tolerate it, and if it helps improve muscle strength. It's a multi-stage study, starting with a smaller group to check safety, then expanding to more boys. Participants will receive a single treatment given through a drip, and their health will be monitored for about two years afterwards.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE2, PHASE3
Sponsor
REGENXBIO Inc.
Einschreibeziel
65
Starten
04 Jan 2023
Geschätzte Fertigstellung
01 Aug 2028

Worum geht es in dieser Studie?

Duchenne muscular dystrophy (DMD) is a genetic condition that causes muscles to become weak and waste away over time. This happens because the body can't make enough of a key protein called dystrophin, which is essential for healthy muscle function. Without it, muscle cells get damaged, leading to ongoing problems.

This study is investigating a new treatment called RGX-202. It's a type of gene therapy, which means it works by introducing new genetic information into the body. Specifically, RGX-202 aims to deliver a piece of genetic code to muscle cells. This code acts like a 'recipe' for a special, smaller version of the dystrophin protein that can still help muscles work.

The main goals of this research are to find out if RGX-202 is safe, if boys with DMD can tolerate the treatment well, and if it helps improve their muscle strength and function. The treatment is given once, through a drip into the vein. Boys in the study will also receive other medicines for a short time to prevent their body from reacting negatively to the gene therapy.

Wichtige Erkenntnisse

  • Tests a new gene therapy (RGX-202) for Duchenne muscular dystrophy.
  • Aims to help muscles make a working version of a missing protein.
  • Treatment is a single dose given into a vein.
  • Study monitors participants for around two years after treatment.
  • Participants will also take short-term medicines to help with the treatment.
  • Open to male participants aged 1 to <12 years old.

Wer könnte berechtigt sein?

This study is looking for boys who have Duchenne muscular dystrophy. They need to be male and at least 1 year old, but less than 12 years old. They should also meet a certain weight requirement (at least 10 kg).

To be considered, participants generally need to have specific changes in their DMD gene and may need to be able to walk a certain distance independently. They should also have been on a stable dose of steroid medication (a common treatment for DMD) for at least 12 weeks. Your doctor will check your child's general health, including their liver and kidney function, to make sure they are healthy enough to take part.

It's important that the child's parent or legal guardian understands the study and agrees to participate, and that they can bring their child to all scheduled appointments and follow the study instructions.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Is my child male and between 1 and 12 years old?
  2. Does my child have a confirmed diagnosis of Duchenne muscular dystrophy?
  3. Can my child walk independently, or with minimal help (depending on the specific group)?
  4. Has my child been on a steady dose of steroid medication for at least 3 months?
  5. Are we able and willing to attend all study appointments over about two years?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, your child will receive the RGX-202 treatment once, through a drip into their vein. Before and during the treatment, your child will also take other medicines for a short time to help prevent any strong reactions to the gene therapy.

The study involves regular visits to the clinic over roughly two years to check your child's health, how they are tolerating the treatment, and if their muscles are improving. These visits will include various assessments, such as physical examinations, blood tests, and tests to measure muscle strength and function. After the main study period, there might be an option to join a separate long-term follow-up study to continue monitoring your child's health.

Potenzielle Risiken und Vorteile

Taking part in any clinical trial involves both potential benefits and risks. The potential benefit of this study is that RGX-202 could help improve muscle strength and overall health for boys with Duchenne muscular dystrophy. However, as this is a new treatment, there might be side effects or risks that are not yet fully known. The study team will carefully monitor your child for any problems, and you'll be given detailed information about known risks. Remember, participation is completely voluntary, and you have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

Standorte (17)

  • Arkansas Children's Hospital
    Verifizierte Postleitzahl
    Little Rock, Vereinigte Staaten· Rekrutierung
  • Stanford School of Medicine /Division of Neuromuscular Medicine
    Verifizierte Postleitzahl
    Palo Alto, Vereinigte Staaten· Rekrutierung
  • Children's Hospital Colorado
    Verifizierte Postleitzahl
    Aurora, Vereinigte Staaten· Rekrutierung
  • Universität von Florida
    Verifizierte Postleitzahl
    Gainesville, Vereinigte Staaten· Rekrutierung
  • Rare Disease Research
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten· Rekrutierung
  • Ann & Robert H. Lurie Kinderkrankenhaus von Chicago
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten· Rekrutierung
  • Universität von Iowa
    Verifizierte Postleitzahl
    Iowa City, Vereinigte Staaten· Rekrutierung
  • University of Massachusetts Chan Medical School
    Verifizierte Postleitzahl
    Worcester, Vereinigte Staaten· Rekrutierung
  • Cincinnati Children's
    Verifizierte Postleitzahl
    Cincinnati, Vereinigte Staaten· Rekrutierung
  • Oregon Health & Science University
    Verifizierte Postleitzahl
    Portland, Vereinigte Staaten· Rekrutierung
  • The University of Texas Southwestern Medical Center
    Verifizierte Postleitzahl
    Dallas, Vereinigte Staaten· Rekrutierung
  • Children's Hospital of the King's Daughters
    Verifizierte Postleitzahl
    Norfolk, United States· Rekrutierung

Häufige Fragen

What is Duchenne muscular dystrophy?

It's a genetic condition that causes muscles to become weak and waste away over time because the body can't make enough of a protein called dystrophin.

What is RGX-202?

It's a new gene therapy treatment designed to help muscle cells make a useful, smaller version of the missing dystrophin protein.

How is the treatment given?

It's given once as a single injection into a vein (like a drip).

Wie lange wird mein Kind an der Studie teilnehmen?

Participants will be monitored for about two years after receiving the treatment, with regular check-ups.

Can girls join the study?

No, this specific study is only for male participants.

Wie Sie mehr erfahren können

Patient Advocacy

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.